Arcturus Therapeutics Holdings Inc.
ARCT
$6.72
$0.172.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.20M | 17.15M | 28.30M | 29.38M | 22.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.20M | 17.15M | 28.30M | 29.38M | 22.77M |
| Cost of Revenue | 24.48M | 23.27M | 29.58M | 34.89M | 43.78M |
| Gross Profit | -17.28M | -6.11M | -1.28M | -5.51M | -21.01M |
| SG&A Expenses | 14.03M | 10.40M | 10.34M | 11.32M | 12.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.50M | 33.66M | 39.92M | 46.21M | 56.16M |
| Operating Income | -31.31M | -16.51M | -11.62M | -16.83M | -33.39M |
| Income Before Tax | -29.08M | -13.45M | -9.18M | -14.08M | -30.01M |
| Income Tax Expenses | -4.00K | -- | 4.00K | -- | -4.00K |
| Earnings from Continuing Operations | -29.08M | -13.45M | -9.18M | -14.08M | -30.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.08M | -13.45M | -9.18M | -14.08M | -30.01M |
| EBIT | -31.31M | -16.51M | -11.62M | -16.83M | -33.39M |
| EBITDA | -30.63M | -15.75M | -10.84M | -16.03M | -32.58M |
| EPS Basic | -1.03 | -0.49 | -0.34 | -0.52 | -1.11 |
| Normalized Basic EPS | -0.65 | -0.31 | -0.21 | -0.32 | -0.69 |
| EPS Diluted | -1.03 | -0.49 | -0.34 | -0.52 | -1.11 |
| Normalized Diluted EPS | -0.65 | -0.31 | -0.21 | -0.32 | -0.69 |
| Average Basic Shares Outstanding | 28.11M | 27.19M | 27.13M | 27.11M | 27.00M |
| Average Diluted Shares Outstanding | 28.11M | 27.19M | 27.13M | 27.11M | 27.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |